Dr. Santosh Kumar Chellapuram, a medical oncology consultant at Star Hospitals in Hyderabad, has recently administered Trastuzumab Deruxtecan, also known as ENHERTU, for the treatment of breast cancer. Trastuzumab Deruxtecan is a targeted therapy specifically designed for unresectable and metastatic HER2-positive breast cancer. Star Hospitals is one of the few centers in India to successfully administer this advanced drug.
Trastuzumab Deruxtecan is a potent Antibody Drug Conjugate that combines a monoclonal antibody with chemotherapy to precisely target HER2-positive breast cancer cells. It has shown significant promise in improving outcomes for patients, particularly for those who have been previously treated with anti-HER2 medicine or for HER2-low breast cancer treated with chemotherapy.
The introduction of Trastuzumab Deruxtecan at Star Hospitals marks a significant milestone in cancer care for the region. It elevates the standards of cancer care and ensures that patients in Telangana and Andhra Pradesh have access to state-of-the-art and cutting-edge therapies.
Ongoing studies have demonstrated that Trastuzumab Deruxtecan is highly effective at shrinking tumors in patients with metastatic breast cancer or breast cancer that cannot be removed by surgery. This targeted therapy has shown positive impacts on disease progression and overall patient outcomes.
Trastuzumab Deruxtecan also demonstrates efficacy in various other cancers, such as lung, stomach, and colon, expressing the HER-2 neu marker. It stands out as one of the rare targeted therapies with exceptional responses applicable across multiple tumor types.
While Trastuzumab Deruxtecan is generally well-tolerated, some patients may experience specific lung-related issues, such as Interstitial Lung Disease. Star Hospitals takes extra precautions post-administration, collaborating closely with a pulmonologist and performing chest CT scans for thorough assessment.
The administration of Trastuzumab Deruxtecan is typically opted for patients with Metastatic Breast Cancer who have exhausted all standard treatment options. It offers potential long-term control of the disease, highlighting its efficacy in addressing challenging cases.
In conclusion, the introduction of Trastuzumab Deruxtecan at Star Hospitals has significantly advanced breast cancer treatment in the region. This targeted therapy has shown remarkable efficacy in shrinking tumors and improving patient outcomes. It provides hope for patients who have exhausted standard treatment options and underscores the commitment of Star Hospitals to elevate the standards of cancer care.
